Barriers and facilitators of persistence with adjuvant osimertinib

Trial Identifier:	D516AR00002
Sponsor:	AstraZeneca
Start Date:	June 2026
Primary Completion Date:	August 2026
Study Completion Date:	August 2026
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.